PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Complete Research Database
0
Major Studies
0
Total Participants
3
Research Articles
N/A
Years of Research
Safety Analysis
Adverse event data from clinical trials
Generally Well-Tolerated
Adverse Event Frequencies
Low (<10%)Moderate (10-25%)High (>25%)
40%
Highnausea
20%
Moderateflushing
13%
Moderateinjection site reaction
11%
Moderateheadache
8%
Lowvomiting
4%
Lowfatigue
Clinical Safety Notes
Timing
GI side effects typically occur during dose escalation
Severity
Most adverse events are mild to moderate in severity
Adherence
Discontinuation rate due to side effects: ~5.3%
Safety
No increased risk of pancreatitis in clinical trials
Monitoring
Regular monitoring recommended for thyroid function
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.